News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
488,272 Results
Type
Article (8018)
Company Profile (143)
Press Release (480111)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166740)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52877)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238195)
Policy (17898)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (500)
Accelerated approval (29)
ADA (18)
Adcomms (1)
Allergies (102)
Alliances (33156)
ALS (121)
Alzheimer's disease (1002)
Antibody-drug conjugate (ADC) (329)
Approvals (10477)
Artificial intelligence (370)
ASCO (160)
Autoimmune disease (241)
Automation (34)
Bankruptcy (263)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (44)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (24)
Bladder cancer (145)
Brain cancer (35)
Breast cancer (544)
Cancer (4033)
Cardiovascular disease (238)
Career advice (245)
Career pathing (1)
CAR-T (187)
CDC (2)
CDMO (30)
Celiac Disease (3)
Cell therapy (514)
Cervical cancer (36)
Clinical research (48468)
Collaboration (1362)
Commercialization (26)
Compensation (1614)
Complete response letters (36)
COVID-19 (774)
CRISPR (68)
C-suite (859)
Cystic fibrosis (89)
Data (6393)
Denatured (4)
Depression (108)
Dermatology (97)
Diabetes (382)
Diagnostics (4267)
Digital health (42)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (170)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (74022)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (237)
Events (88829)
Executive appointments (738)
Eye disease (3)
FDA (12683)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (999)
Gene editing (132)
Generative AI (13)
Gene therapy (352)
GLP-1 (312)
Government (953)
Grass and pollen (2)
Guidances (281)
Healthcare (9396)
Hematology (95)
HIV (56)
Huntington's disease (28)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (81)
Immunology and inflammation (113)
Immuno-oncology (71)
Indications (185)
Infectious disease (981)
Inflammatory bowel disease (141)
Inflation Reduction Act (4)
Influenza (89)
Intellectual property (271)
Interviews (41)
IPO (12400)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (19)
Kidney disease (89)
Layoffs (59)
Legal (5195)
Licensing (50)
Liver cancer (47)
Longevity (27)
Lung cancer (580)
Lung diease (9)
Lymphoma (269)
Machine learning (30)
Management (3)
Manufacturing (620)
Marketing (21)
MASH (122)
Medical affairs (2)
Medical device (8716)
Medtech (8906)
Mergers & acquisitions (14458)
Metabolic disorders (771)
mRNA (73)
Multiple sclerosis (117)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (242)
Neuropsychiatric disorders (40)
Neuroscience (1953)
Neurotech (2)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (242)
Opinion (10)
Ovarian cancer (181)
Pain (194)
Pancreatic cancer (232)
Parkinson's disease (217)
Partnered (12)
Patents (525)
Patient advocacy (3)
Patient recruitment (549)
Patient selection (47)
Peanut (33)
People (41534)
Peptides (16)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15643)
Phase 2 (21657)
Phase 3 (14622)
Pipeline (8496)
Policy (18)
Postmarket research (1570)
Preclinical (6598)
Press Release (34)
Prostate cancer (209)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (626)
Real estate (3025)
Recruiting (6)
Regenerative medicine (13)
Regulatory (15197)
Reports (23)
Research institute (592)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (110)
Series A (177)
Series B (126)
Service/supplier (5)
Sickle cell disease (66)
Spinal muscular atrophy (93)
Sponsored (5)
Startups (2021)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (56)
Tariffs (2)
Vaccines (355)
Venture capital (17)
Weight loss (77)
Wet AMD (3)
Women's health (100)
Date
Today (79)
Last 7 days (486)
Last 30 days (1749)
Last 365 days (19238)
2026 (15906)
2025 (19251)
2024 (22987)
2023 (26538)
2022 (34587)
2021 (37169)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24264)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (232)
Alabama (80)
Alaska (2)
Arizona (322)
Arkansas (12)
Asia (18074)
Australia (2124)
California (12974)
Canada (3374)
China (586)
Colorado (532)
Connecticut (453)
Delaware (230)
Europe (24809)
Florida (1949)
Georgia (411)
Hawaii (3)
Idaho (46)
Illinois (780)
India (62)
Indiana (335)
Iowa (19)
Japan (458)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (27)
Maryland (1281)
Massachusetts (8475)
Michigan (322)
Minnesota (602)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (134)
New Hampshire (61)
New Jersey (2852)
New Mexico (12)
New York (3038)
North Carolina (1374)
North Dakota (4)
Northern California (6566)
Ohio (305)
Oklahoma (15)
Oregon (17)
Pennsylvania (2415)
Puerto Rico (24)
Rhode Island (31)
South America (407)
South Carolina (81)
South Dakota (1)
Southern California (5418)
Tennessee (128)
Texas (2140)
United States (42021)
Utah (396)
Vermont (1)
Virginia (168)
Washington D.C. (39)
Washington State (997)
West Virginia (1)
Wisconsin (82)
Wyoming (1)
488,272 Results for "oravax inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.
October 7, 2022
·
6 min read
Pharm Country
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
Oramed Pharmaceuticals Inc. today announced several updates for its majority-owned company Oravax Medical Inc.
July 21, 2021
·
7 min read
Drug Development
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants.
December 14, 2021
·
5 min read
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Business
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company.
December 29, 2021
·
6 min read
Pharm Country
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
Oramed Pharmaceuticals Inc. announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax’s oral COVID-19 vaccine, currently in development.
December 29, 2021
·
6 min read
Drug Development
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
MyMD Pharmaceuticals, Inc. reported that its subsidiary Oravax Medical Inc., partially owned with its majority partner Oramed Pharmaceuticals Inc., is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.
August 10, 2021
·
5 min read
Business
Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
Oramed today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed’s majority-owned subsidiary Oravax Medical Inc.
November 18, 2021
·
8 min read
Drug Development
Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial
Oramed Pharmaceuticals Inc. today announced that its majority-owned subsidiary, Oravax Medical Inc. ( www.ora-vax.com ), has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral COVID-19 vaccine and preparations to begin the trials are now underway.
October 29, 2021
·
5 min read
Business
Premas Biotech and Oravax Medical to Test Their Triple Antigen Oral Vaccine Candidate Against Omicron Variant of Concern
Premas Biotech announced today that its joint venture Oravax will initiate testing of their oral virus-like particle (VLP) vaccine candidate against Omicron variant of SARS-CoV 2 virus through preclinical, in vitro and challenge studies to assess its efficacy for the new mutant strain.
December 1, 2021
·
2 min read
1 of 48,828
Next
